Actinium Pharmaceuticals (NYSE:ATNM) Stock Rating Upgraded by StockNews.com

Actinium Pharmaceuticals (NYSE:ATNM) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Friday.

Separately, HC Wainwright reiterated a “buy” rating and set a $4.00 price objective on shares of Actinium Pharmaceuticals in a research note on Tuesday, April 1st. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $7.40.

Actinium Pharmaceuticals Stock Performance

NYSE:ATNM opened at $1.21 on Friday. Actinium Pharmaceuticals has a one year low of $1.03 and a one year high of $10.24. The business’s 50-day simple moving average is $1.28 and its 200 day simple moving average is $1.39. The stock has a market cap of $37.75 million, a price-to-earnings ratio of -0.87 and a beta of -0.27.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Geode Capital Management LLC raised its stake in shares of Actinium Pharmaceuticals by 3.0% during the third quarter. Geode Capital Management LLC now owns 686,153 shares of the company’s stock valued at $1,290,000 after purchasing an additional 19,843 shares in the last quarter. Northern Trust Corp boosted its position in Actinium Pharmaceuticals by 4.9% during the 4th quarter. Northern Trust Corp now owns 251,930 shares of the company’s stock worth $317,000 after acquiring an additional 11,812 shares during the period. Los Angeles Capital Management LLC increased its stake in Actinium Pharmaceuticals by 25.0% in the 4th quarter. Los Angeles Capital Management LLC now owns 213,950 shares of the company’s stock valued at $270,000 after buying an additional 42,770 shares during the period. Renaissance Technologies LLC boosted its position in Actinium Pharmaceuticals by 49.9% during the fourth quarter. Renaissance Technologies LLC now owns 190,400 shares of the company’s stock valued at $240,000 after purchasing an additional 63,400 shares during the last quarter. Finally, Squarepoint Ops LLC raised its holdings in Actinium Pharmaceuticals by 25.4% during the fourth quarter. Squarepoint Ops LLC now owns 183,262 shares of the company’s stock valued at $231,000 after buying an additional 37,159 shares in the last quarter. Institutional investors own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).